Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab

Tonyali, Onder; Coskun, UĞUR; Yuksel, Sinemis; İNANÇ, MEVLÜDE; Bal, Oznur; Akman, Tulay; Yazilitas, Dogan; Ulas, Arife; KÜÇÜKÖNER, MEHMET; Aksoy, Asude; Demirci, Umut; UYSAL, MÜKREMİN; TANRIVERDİ, ÖZGÜR; Gunaydin, Yusuf; Sumbul, Ahmet; Yildiz, Ramazan; Karaca, Halit; Oksuzoglu, Berna; Ciltas, Aydin; Buyukberber, Suleyman; Benekli, Mustafa

doi:10.1016/j.breast.2015.11.006

Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab

Atıf İçin Kopyala

Tonyali O., Coskun U., Yuksel S., İNANÇ M., Bal O., Akman T., ...Daha Fazla

BREAST, cilt.25, ss.22-26, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 25
Basım Tarihi: 2016
Doi Numarası: 10.1016/j.breast.2015.11.006
Dergi Adı: BREAST
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.22-26
Anahtar Kelimeler: Breast cancer, Adjuvant therapy, Trastuzumab, Brain metastasis, CENTRAL-NERVOUS-SYSTEM, RANDOMIZED-TRIALS, RECEPTOR STATUS, SURVIVAL, METAANALYSIS, CHEMOTHERAPY, SUBTYPES, THERAPY, NETWORK
Gazi Üniversitesi Adresli: Evet

Özet

Purpose: The aim of this study was to determine risk factors for brain metastasis as the first site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who received adjuvant trastuzumab.